In the News

Lloryn Hubbard discusses how life science companies can address the disparities within clinical trials and health equity.

Jai Balkissoon and Evan Zynda highlight the key trends and challenges in cell and gene therapy, and explore the latest advancements in cell therapy for cancer treatment.

Our experts describe an intelligent drug development paradigm that enables small pharma to implement a truth-seeking early development approach like those used by progressive big pharma companies.

Robert King explains that solutions are on the horizon that will help overcome the current bottlenecks and other challenges that are occurring in early drug development.

Rose Blackburne discusses health equity and racial bias in pharma and how to address inequities in access and care.

Customers face four key decision points early in the development life cycle that are critical to the success of a decentralized clinical trial (DCT) strategy. In this article, our experts discuss each of those four decisions to help build a strong data foundation for DCTs with a functional service provider model.

Our experts comment on the challenges, trends and focus of clinical research today.

Panteli Theocharous discusses the current landscape and future outlook for clinical research in cell and gene therapy, stressing the importance of partnerships with various stakeholders.

Endpoints are needed throughout the vaccine development life cycle. In this article, the authors discuss how to develop, assess and select endpoints at each development step.